CORT (Drugmakers) Stock Valuation & Fair Value
Significantly overvaluedCORT (Drugmakers) trades at a current P/E of 43.5, about 49% above its historical normal valuation, with a forward growth estimate of 74.7% and a PEG of 0.58. Priced at its historical normal P/E of 29.2 on the same blended earnings, the 2026-10-30 close of $81.12 corresponds to about $54.60 a share. This is a valuation reference, not a price target.
How to read these numbers: the PEG ratio and current P/E versus normal P/E.
Valuation flags
- Overvalued by 49%
- Misses analyst estimates often (64%)
Frequently asked questions
Is CORT overvalued?
At a current P/E of 43.5 versus its historical normal P/E of 29.2, CORT trades about 49% above its typical valuation, with a PEG of 0.58 on 74.7% forward growth. tickerseer currently rates it significantly overvalued.
What is CORT's fair value and PEG?
CORT trades at a current P/E of 43.5 against a historical normal P/E of 29.2, a PEG of 0.58, and a forward growth estimate of 74.7%. Priced at its historical normal P/E of 29.2 on the same blended earnings, the 2026-10-30 close of $81.12 corresponds to about $54.60 a share. This is a valuation reference, not a price target.
Has tickerseer's rating of CORT changed?
tickerseer's rating has been significantly overvalued since 2026-10-31.
Industry: Drugmakers. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and an AI research note where we have one. Options setups and metric history are part of the paid plans.
Get the free weekly earnings preview
One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.
It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.